Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations

Transfusion Medicine Reviews

Volumn 30, Issue 4, 2016, Pages 159-164

  Hendrickson, Jeanne E ^a   Delaney, Meghan ^b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c Bloodworks NW ^*  (United States)

Author keywords

Alloimmunization; Hemolytic disease of the fetus and newborn; Red blood cell

Indexed keywords

ALLOANTIBODY; BLOOD GROUP ANTIGEN; ERYTHROCYTE ANTIGEN; IMMUNOGLOBULIN; RHESUS ANTIBODY; RHESUS D ANTIBODY; RHESUS D ANTIGEN; ANTIBODY;

ALLOIMMUNIZATION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; DIAGNOSTIC TEST; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FETUS; FETUS DEVELOPMENT; FETUS DISEASE; FETUS HEMOLYTIC DISEASE; HEMOLYTIC ANEMIA; HUMAN; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INTRAUTERINE BLOOD TRANSFUSION; MEDICAL PRACTICE; NEWBORN; NEWBORN HEMOLYTIC DISEASE; NON INVASIVE PROCEDURE; NONHUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PROTEIN GLYCOSYLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIZATION; ANIMAL; BLOOD; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; ERYTHROCYTE; FEMALE; HEMATOLOGIC DISEASE; HEMATOLOGY; IMMUNOLOGY; MOUSE; PREGNANCY; PRENATAL DIAGNOSIS; TRANSGENIC MOUSE; TRENDS;

ANIMALS; ANTIBODIES; BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; ERYTHROBLASTOSIS, FETAL; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; HEMATOLOGIC DISEASES; HEMATOLOGY; HUMANS; ISOANTIBODIES; MICE; MICE, TRANSGENIC; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 84994839931     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2016.05.008     Document Type: Review

References (65)

1. [1] Reid, ME, Lomas-Francis, C, The blood group antigen facts book. 2nd ed., 2004, Elsevier Academic Press, Amsterdam.
2. [2] Moise, KJ Jr., Argoti, PS, Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 120 (2012), 1132–1139.
3. [3] Delaney, M, Matthews, DC, Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program 2015 (2015), 146–151.
4. [4] Eder, AF, Update on HDFN: new information on long-standing controversies. Immunohematology 22 (2006), 188–195.
5. [5] Markham, KB, Rossi, KQ, Nagaraja, HN, O'Shaughnessy, RW, Hemolytic disease of the fetus and newborn due to multiple maternal antibodies. Am J Obstet Gynecol, 213, 2015, 68 [e1-5].
6. [6] Moise, KJ Jr., Non–anti-D antibodies in red-cell alloimmunization. Eur J Obstet Gynecol Reprod Biol 92 (2000), 75–81.
7. [7] Hadley, AG, Wilkes, A, Goodrick, J, Penman, D, Soothill, P, Lucas, G, The ability of the chemiluminescence test to predict clinical outcome and the necessity for amniocenteses in pregnancies at risk of haemolytic disease of the newborn. Br J Obstet Gynaecol 105 (1998), 231–234.
8. [8] Nance, SJ, Nelson, JM, Horenstein, J, Arndt, PA, Platt, LD, Garratty, G, Monocyte monolayer assay: an efficient noninvasive technique for predicting the severity of hemolytic disease of the newborn. Am J Clin Pathol 92 (1989), 89–92.
9. [9] Kapur, R, Della Valle, L, Sonneveld, M, Hipgrave Ederveen, A, Visser, R, Ligthart, P, et al. Low anti-RhD IgG-fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. Br J Haematol 166 (2014), 936–945.
10. [10] Sonneveld, ME, Plom, R, Admiraal, J, Koeleman, C, Hipgrave-Ederveen, A, Koelewijn, J, et al. IgG alloantibodies agianst RBC induced by pregnancy or transfusion have unique glycosylation patterns which correlate with clinical outcomes of hemolytic disease of the fetus or newborn. Blood ASH annual meeting supplement, 2015 [Abstract 660].
11. [11] Vaughan, JI, Manning, M, Warwick, RM, Letsky, EA, Murray, NA, Roberts, IA, Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 338 (1998), 798–803.
12. [12] Daniels, G, Hadley, A, Green, CA, Causes of fetal anemia in hemolytic disease due to anti-K. Transfusion 43 (2003), 115–116.
13. [13] Wagner, FF, Flegel, WA, RHD gene deletion occurred in the rhesus box. Blood, 95, 2000, 3662.
14. [14] Finning, K, Martin, P, Summers, J, Daniels, G, Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion, 47, 2007, 2126.
15. [15] Finning, KM, Martin, PG, Soothill, PW, Avent, ND, Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion, 42, 2002, 1079.
16. [16] Ahaded, A, Brossard, Y, Debbia, M, Lambin, P, Quantitative determination of anti-K (KEL1) IgG and IgG subclasses in the serum of severely alloimmunized pregnant women by ELISA. Transfusion 40 (2000), 1239–1245.
17. [17] Lambin, P, Debbia, M, Puillandre, P, Brossard, Y, IgG1 and IgG3 anti-D in maternal serum and on the RBCs of infants suffering from HDN: relationship with the severity of the disease. Transfusion 42 (2002), 1537–1546.
18. [18] Oepkes, D, van Kamp, IL, Simon, MJ, Mesman, J, Overbeeke, MA, Kanhai, HH, Clinical value of an antibody-dependent cell-mediated cytotoxicity assay in the management of Rh D alloimmunization. Am J Obstet Gynecol 184 (2001), 1015–1020.
19. [19] de Haas, M, Thurik, FF, Koelewijn, JM, van der Schoot, CE, Haemolytic disease of the fetus and newborn. Vox Sang 109 (2015), 99–113.
20. [20] Higel, F, Seidl, A, Sorgel, F, Friess, W, N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and fc fusion proteins. Eur J Pharm Biopharm 100 (2016), 94–100.
21. [21] Kapur, R, Kustiawan, I, Vestrheim, A, Koeleman, CA, Visser, R, Einarsdottir, HK, et al. A prominent lack of IgG1-fc fucosylation of platelet alloantibodies in pregnancy. Blood 123 (2014), 471–480.
22. [22] practice bulletin no, ACOG, 75: management of alloimmunization during pregnancy. Obstet Gynecol 108 (2006), 457–464.
23. [23] Lindenburg, IT, Smits-Wintjens, VE, van Klink, JM, Verduin, E, van Kamp, IL, Walther, FJ, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol, 206, 2012, 141 [e1-8].
24. [24] Ruma, MS, Moise, KJ Jr., Kim, E, Murtha, AP, Prutsman, WJ, Hassan, SS, et al. Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. Am J Obstet Gynecol, 196, 2007, 138 [e1-6].
25. [25] Schwartz, J, Winters, JL, Padmanabhan, A, Balogun, RA, Delaney, M, Linenberger, ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 28 (2013), 145–284.
26. [26] Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics, 114, 2004, 297–316.
27. [27] Rath, ME, Smits-Wintjens, VE, Walther, FJ, Lopriore, E, Hematological morbidity and management in neonates with hemolytic disease due to red cell alloimmunization. Early Hum Dev 87 (2011), 583–588.
28. [28] Smits-Wintjens, VE, Rath, ME, van Zwet, EW, Oepkes, D, Brand, A, Walther, FJ, et al. Neonatal morbidity after exchange transfusion for red cell alloimmune hemolytic disease. Neonatology 103 (2013), 141–147.
29. [29] Corvaglia, L, Legnani, E, Galletti, S, Arcuri, S, Aceti, A, Faldella, G, Intravenous immunoglobulin to treat neonatal alloimmune haemolytic disease. J Matern Fetal Neonatal Med 25 (2012), 2782–2785.
30. [30] Elalfy, MS, Elbarbary, NS, Abaza, HW, Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn—a prospective randomized controlled trial. Eur J Pediatr 170 (2011), 461–467.
31. [31] Hauschner, H, Rosenberg, N, Seligsohn, U, Mendelsohn, R, Simmonds, A, Shiff, Y, et al. Persistent neonatal thrombocytopenia can be caused by IgA antiplatelet antibodies in breast milk of immune thrombocytopenic mothers. Blood 126 (2015), 661–664.
32. [32] Santhanakrishnan, M, Tormey, CA, Natarajan, P, Liu, J, Hendrickson, JE, Clinically significant anti-KEL RBC alloantibodies are transferred by breast milk in a murine model. Vox Sang, 2016, 10.1111/vox.12387.
33. [33] Van de Perre, P, Transfer of antibody via mother's milk. Vaccine 21 (2003), 3374–3376.
34. [34] Paveglio, S, Puddington, L, Rafti, E, Matson, AP, FcRn-mediated intestinal absorption of IgG anti-IgE/IgE immune complexes in mice. Clin Exp Allergy 42 (2012), 1791–1800.
35. [35] Callum, JL, Waters, JH, Shaz, BH, Sloan, SR, Murphy, MF, The AABB recommendations for the choosing wisely campaign of the American Board of Internal Medicine. Transfusion, 54, 2014, 2344.
36. [36] van der Schoot, CE, Tax, GH, Rijnders, RJ, de Haas, M, Christiaens, GC, Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev, 17, 2003, 31.
37. [37] Bowman, JM, Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given?. Am J Obstet Gynecol 151 (1985), 289–294.
38. [38] Sandler, SG, Flegel, WA, Westhoff, CM, Denomme, GA, Delaney, M, Keller, MA, et al. It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. Transfusion 55 (2015), 680–689.
39. [39] Kacker, S, Vassallo, R, Keller, MA, Westhoff, CM, Frick, KD, Sandler, SG, et al. Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. Transfusion 55:9 (2015), 2095–2103.
40. [40] Anderson, B, Shad, AT, Gootenberg, JE, Sandler, SG, Successful prevention of post-transfusion Rh alloimmunization by intravenous rho (D) immune globulin (WinRho SD). Am J Hematol 60 (1999), 245–247.
41. [41] Laspina, S, O'Riordan, JM, Lawlor, E, Murphy, WG, Prevention of post-transfusion RhD immunization using red cell exchange and intravenous anti-D immunoglobulin. Vox Sang 89 (2005), 49–51.
42. [42] Nester, TA, Rumsey, DM, Howell, CC, Gilligan, DM, Drachman, JG, Maier, RV, et al. Prevention of immunization to D + red blood cells with red blood cell exchange and intravenous Rh immune globulin. Transfusion 44 (2004), 1720–1723.
43. [43] Schonewille, H, Klumper, FJ, van de Watering, LM, Kanhai, HH, Brand, A, High additional maternal red cell alloimmunization after rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus. Am J Obstet Gynecol, 196, 2007, 143 [e1].
44. [44] Schonewille, H, Prinsen-Zander, KJ, Reijnart, M, van de Watering, L, Zwaginga, JJ, Meerman, RH, et al. Extended matched intrauterine transfusions reduce maternal Duffy, Kidd, and S antibody formation. Transfusion 55 (2015), 2912–2919.
45. [45] Brinc, D, Lazarus, AH, Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am Soc Hematol Educ Program, 2009, 185–191.
46. [46] Kumpel, BM, On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis). Immunol Lett 82 (2002), 67–73.
47. [47] Kapur, R, Della Valle, L, Verhagen, OJ, Hipgrave Ederveen, A, Ligthart, P, de Haas, M, et al. Prophylactic anti-D preparations display variable decreases in fc-fucosylation of anti-D. Transfusion 55 (2015), 553–562.
48. [48] Goossens, D, da Silva, N, Metral, S, Cortes, U, Callebaut, I, Picot, J, et al. Mice expressing RHAG and RHD human blood group genes. PLoS One, 8, 2013, e80460.
49. [49] Bernardo, L, Denomme, GA, Shah, K, Lazarus, AH, RhD specific antibodies are not detectable in HLA-DRB1(*)1501 mice challenged with human RhD positive erythrocytes. Adv Hematol, 2014, 2014, 470242.
50. [50] Finn, R, Clarke, CA, Donohoe, WT, Mc, CR, Sheppard, PM, Lehane, D, et al. Experimental studies on the prevention of Rh haemolytic disease. Br Med J 1 (1961), 1486–1490.
51. [51] Kumpel, BM, Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang 93 (2007), 99–111.
52. [52] Hendrickson, JE, Hod, EA, Spitalnik, SL, Hillyer, CD, Zimring, JC, Storage of murine red blood cells enhances alloantibody responses to an erythroid-specific model antigen. Transfusion 50 (2010), 642–648.
53. [53] Hendrickson, JE, Hod, EA, Cadwell, CM, Eisenbarth, SC, Spiegel, DA, Tormey, CA, et al. Rapid clearance of transfused murine red blood cells is associated with recipient cytokine storm and enhanced alloimmunogenicity. Transfusion 51 (2011), 2445–2454.
54. [54] Smith, NH, Hod, EA, Spitalnik, SL, Zimring, JC, Hendrickson, JE, Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood 119 (2012), 1566–1569.
55. [55] Hendrickson, JE, Desmarets, M, Deshpande, SS, Chadwick, TE, Hillyer, CD, Roback, JD, et al. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion 46 (2006), 1526–1536.
56. [56] Schenten, D, Medzhitov, R, The control of adaptive immune responses by the innate immune system. Adv Immunol 109 (2011), 87–124.
57. [57] Stowell, SR, Arthur, CM, Girard-Pierce, KR, Sullivan, HC, Santhanakrishnan, M, Natarajan, P, et al. Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model. Haematologica 100 (2015), e394–e397.
58. [58] Brinc, D, Le-Tien, H, Crow, AR, Freedman, J, Lazarus, AH, IgG-mediated immunosuppression is not dependent on erythrocyte clearance or immunological evasion: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the newborn?. Br J Haematol 139 (2007), 275–279.
59. [59] Brinc, D, Le-Tien, H, Crow, AR, Siragam, V, Freedman, J, Lazarus, AH, Immunoglobulin G-mediated regulation of the murine immune response to transfused red blood cells occurs in the absence of active immune suppression: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the fetus and newborn?. Immunology 124 (2008), 141–146.
60. [60] Bernardo, L, Yu, H, Amash, A, Zimring, JC, Lazarus, AH, IgG-mediated immune suppression to erythrocytes by polyclonal antibodies can occur in the absence of activating or inhibitory Fcgamma receptors in a full mouse model. J Immunol 195 (2015), 2224–2230.
61. [61] Stowell, SR, Liepkalns, JS, Hendrickson, JE, Girard-Pierce, KR, Smith, NH, Arthur, CM, et al. Antigen modulation confers protection to red blood cells from antibody through Fcgamma receptor ligation. J Immunol 191 (2013), 5013–5025.
62. [62] Zimring, JC, Cadwell, CM, Spitalnik, SL, Antigen loss from antibody-coated red blood cells. Transfus Med Rev 23 (2009), 189–204.
63. [63] Taylor, RP, Lindorfer, MA, Fcgamma-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood 125 (2015), 762–766.
64. [64] Sullivan, HC, Arthur, CM, Patel, SR, Hendrickson, JE, Lazarus, AH, Stowell, SR, Anti-RhD mediates loss of RhD antigen following anti-RhD infusion. Blood, 126, 2015, 3570.
65. [65] Girard-Pierce, KR, Stowell, SR, Smith, NH, Arthur, CM, Sullivan, HC, Hendrickson, JE, et al. A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation. Blood 122 (2013), 1793–1801.